Substance Use in Pregnancy | Mishka Terplan, MD, MPH
This lecture reviews:
- History of opioid epidemics in women
- Pregnant women and stigma
- Epidemiology of drug use in pregnancy
- Outcomes of perinatal drug exposure (alcohol, opioids, tobacco)
- Treatment of addiction in pregnancy (opioids)
- Neonatal abstinence syndrome and newborn reporting
PRICE/PURCHASE -- $50
You must sign in or register register on this site before purchasing using the link on the upper right corner of this page. Only after registering will you see the "Add to Cart" button. To purchase, scroll to the bottom of the page and click "Add to Cart."
PHYSICIANS: The California Society of Addiction Medicine (CSAM) is accredited by the Institute for Medical Quality/California Medical Association to provide continuing medical education for physicians. CSAM takes responsibility for the content, quality and scientific integrity of this CME activity.
CSAM designates this live educational activity for a maximum of 1 AMA PRA Category 1 Credit™ Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may also be applied to the CMA Certification in Continuing Medical Education.
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 1 AMA/PRA Category 1 Credits™ for completing the Review Course.
Continuing education credit is also available for nurses, psychologists, pharmacists, physician assistants, therapists, and drug abuse counselors.
- Addiction medicine specialists who want an overview of the latest developments in the field and their relevance to clinical practice
- Primary care clinicians who want to get a better understanding of addiction and manage patients with addictions in their practice
- Public health officials who want an understanding of the current state of addiction treatment
- Non-physicians who are involved in the treatment of addiction
As a result of participating in this lecture learners should have a working knowledge of the following topics, essential to competency in addiction medicine and identify areas where more study may be needed:
- Epidemiology of alcoholism and addiction in women (including tobacco)
- Overview of screening tools designed for this population
- Overview of office-based brief interventions with pregnant patients and new moms,
- Changes in drug dosing/volume of distribution or metabolism during pregnancy
- Effects on the fetus of mode of maternal drug use (oral, intravenous, intranasal, inhalation, IM) and type of drug used
- Obstetrical complications and pregnancy-related disorders and complications involving alcohol, tobacco and drugs (preterm, SABO, ID, nutrition, routine medical care etc)
- Routes of fetal/neonatal exposure to alcohol, tobacco and drugs (placenta/nursing/second hand), fetal/perinatal effects of such exposure and if there are peaks of vulnerability (neurological/physical/ cognitive)
- Pharmacologic and non-pharmacologic intervention for neonatal intoxication and withdrawal for opioids and sedatives,
- Clinical management of the alcoholic/addicted/smoking pregnant patient (evidence-based, pharmacologic, residential, etc),
- Include any comments on treatment modalities that work better or worse on this population or are contraindicated and why,
- FAS, cognitive and behavioral diagnoses secondary to in-utero alcohol and drug exposure.*
- Management of adverse impact of alcohol on the fetus,
- Ethical/legal/liability considerations.
- Briefly describe the design, outcome, limitations and clinical implications of the MOTHERS Study.
Mishka Terplan, MD, MPH
Dr. Terplan is board certified in both Obstetrics and Gynecology and Addiction Medicine. His research, clinical and advocacy interests lie along the intersection of reproductive health and addiction lifecourses. He has represented both ACOG and ASAM on taskforces and workgroups and currently is Medical Director of Behavioral Health System Baltimore, the local behavioral health authroity and adjunct faculty in Epidemiology and Public Health at the University of Maryland School of Medicine.
Dr. Terplan has no relevant financial relationships to disclose.
- 1.00 AMA Category 1
- 1.00 Attendance